AR072688A1 - Nucleosidos y nucleotidos biciclicos como agentes terapeuticos - Google Patents

Nucleosidos y nucleotidos biciclicos como agentes terapeuticos

Info

Publication number
AR072688A1
AR072688A1 ARP090102498A ARP090102498A AR072688A1 AR 072688 A1 AR072688 A1 AR 072688A1 AR P090102498 A ARP090102498 A AR P090102498A AR P090102498 A ARP090102498 A AR P090102498A AR 072688 A1 AR072688 A1 AR 072688A1
Authority
AR
Argentina
Prior art keywords
substituted
optionally substituted
group
optionally
alkyl
Prior art date
Application number
ARP090102498A
Other languages
English (en)
Inventor
Richard Hufton
Saba Jahangiri
George Kukolj
Jianmin Duan
Barbara Frey
Michael John Lilly
Richard Bethell
Silas Bond
Alistair George Draffan
Michael Harding
Edward Tyndall
Paula Francom
Original Assignee
Boehringer Ingelheim Int
Biota Scient Man
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Biota Scient Man filed Critical Boehringer Ingelheim Int
Publication of AR072688A1 publication Critical patent/AR072688A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso y métodos de elaboracion de nucleosidos y nucleotidos bicíclicos para el tratamiento y la prevencion de enfermedades infecciosas y proliferativas, incluyendo infecciones microbianas, cáncer, hepatitis C. Reivindicacion 1: Un compuesto, caracterizado porque es de la formula (1) donde la línea ondulada define el ingrediente farmacéutico activo como un nucleosido o nucleotido D o L; A se selecciona entre el grupo que consiste en -O-, -S-, -CH2-, -CHF-, -CF2-, y -NR-; R1', R2, R2', R3, R3', y R4' se seleccionan en forma independiente entre el grupo que consiste en -H, halogeno, -OH, -NHOH, -NHNH2, -N3, -CN, -OCOHNC(CH3)2, -COOH, -CONH2, -C(S)NH2, -COOR, -R, -OR, -SR, -SSR, - NHR, y -NR2, o R2 y R2' juntos o R3 y R3' juntos representan =O, =S, o =L'-Y', donde L' se selecciona entre el grupo que consiste en N, CH, CF, CCI, y CBr y Y' se selecciona entre el grupo que consiste en H, halogeno, N3, metilo, etilo, y CN; R es en forma independiente halogeno, -H, -OH, -SH, -CN, S(C1-4alquilo), -NO2, NH2, -NHNH2, -N3, -NR'R' donde cada R' es en forma independiente H o C1-4 alquilo, -C(S)NH2, -CH3, -CH2OH, -CN2NH2, -CH2NH3+, -COOH, -COOCH3, -COOCH2CH3, -CONHCH3, -CONH2, -CF3, -N(CH3)2, -NHCOCH3, -NBHCONH2, -NHCNHNH2, -ONH2, -CH2OCH3, -O(CH2)CH3, COOC1-4alquilo, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, acilo opcionalmente sustituido, arilalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, fenilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, alquiloxi opcionalmente sustituido, alqueniloxi opcionalmente sustituido, alquinoxi opcionalmente sustituido, ariloxi opcionalmente sustituido, aciloxi opcionalmente sustituido, oxiacilo opcionalmente sustituido, arilalcoxi opcionalmente sustituido, heterocicloxi opcionalmente sustituido, heteroariloxi opcionalmente sustituido, cicloalcoxi opcionalmente sustituido, cicloalquenoxi opcionalmente sustituido, amino opcionalmente sustituido, aminoacilo opcionalmente sustituido, aminoaciloxi opcionalmente sustituido, acilamino opcionalmente sustituido, oxiacilamino opcionalmente sustituido, oxiaciloxi opcionalmente sustituido, acilimino opcionalmente sustituido, aciliminoxi opcionalmente sustituido, oxiacilimino opcionalmente sustituido, aminotioacilo opcionalmente sustituido, tioacilamino opcionalmente sustituido, aminosulfinilo opcionalmente sustituido, aminosulfonilo opcionalmente sustituido, tio opcionalmente sustituido, tioalquilo opcionalmente sustituido, tioacilo opcionalmente sustituido, tioaciloxi opcionalmente sustituido, oxitioacilo opcionalmente sustituido, oxitioaciloxi opcionalmente sustituido, fosforilamino opcionalmente sustituido, sulfinilo opcionalmente sustituido, sulfonilo opcionalmente sustituido, sulfinilamino opcionalmente sustituido, sulfonilamino opcionalmente sustituido, oxisulfinilamino opcionalmente sustituido, y oxisulfonilamino opcionalmente sustituido; L se selecciona entre el grupo que consiste en -O, -S, -NH, -NR, -CY3, -CY2O, -CY2NH, -CY2, -CY2CY2, -CY2OCY2, -CY2SCY2, y -CY2NHCY2; Y se selecciona en forma independiente entre el grupo que consiste en -H, halogeno, -R, -OR, y -NR2; R5 se selecciona entre el grupo que consiste en -OH, -R, -OR, -NR2, o una porcion monofosfato, difosfato o trifosfato o mimético del mismo; Base es un grupo de la formula (2) donde ===== es un enlace simple o doble; Z1, Z3, y Z4 se seleccionan en forma independiente entre el grupo que consiste en >C-CONHR, >C-CONR2, >C-C(S)NH2, >C-COOR, >C-R, >C-OR, >C-SR, >C-NHR, >C-NR2, >C-heteroarilo opcionalmente sustituido, >C-alquilo opcionalmente sustituido, y >C-G; Z2 se selecciona entre el grupo que consiste en >C-NH2 y >C=O; G se selecciona en forma independientemente entre el grupo que consiste en -H, -F, -Cl, -I, -NH2, -NHCH3, -CN, -COOH, -CSNH2, -C:::CH, -C:::CCH3, -C:::CCH2OH, -C:::C-Si(CH3)3, -CONH2, -CONHCH3, -CONH-fenilo, -CONH-metilfenilo, tiazol, oxazol, imidazol, imidazolina, triazol, y tetrazol, y cuando el compuesto comprende dos o más grupos G, los G son idénticos o diferentes; y cuando A es O; R1', R3, R4', y R5 son H; L es O; y R2' y R3' son OH; entonces R2 es halogeno, OH, NHOH, NHNH2, N3, CN, OCOCHNC(CH3)2, COOH, CONH2, C(S)NH2, COOR, R6, o, SR, SSR, NHR, o NR2, y R6 es halogeno, OH, SH, CN, S(C1-4 alquilo), NO2, NH2, NHNH2, N3, NR'R' donde cada R' es en forma independiente H o C1-4 alquilo, C(S)NH2, CH3, CH2OH, CH2NH2, CH2NH3+, COOH, COOCH3, COOCH2CH3, CONHCH3, CONH2, CF3, N(CH3)2, NHCOCH3, NHCONH2, NHCNHNH2, ONH2, CH2OCH3, O(CH2)CH3, COO(C1-4 alquilo), alquilo sustituido, alquenilo sustituido, alquinilo sustituido, arilo sustituido, acilo sustituido, arilalquilo sustituido, cicloalquilo sustituido, cicloalquenilo sustituido, fenilo sustituido, heteroarilo sustituido, heterociclilo sustituido, alquiloxi sustituido, alqueniloxi sustituido, alquinoxi sustituido, ariloxi sustituido, aciloxi sustituido, oxiacilo sustituido, arilalcoxi sustituido, heterocicloxi sustituido, heteroariloxi sustituido, cicloalcoxi sustituido, cicloalqueniloxi sustituido, amino sustituido, aminoacilo sustituido, aminoaciloxi sustituido, acilamino sustituido, oxiacilamino sustituido, oxiaciloxi sustituido, acilimino sustituido, adiliminoxi sustituido, oxiacilimino sustituido, aminotioacilo sustituido, tioacilamino sustituido, aminosulfinilo sustituido, aminosulfonilo sustituido, tio sustituido, tioalquilo sustituido, tioacilo sustituido, tioaciloxi sustituido, oxitioacilo sustituido, oxitioaciloxi sustituido, fosforilamino sustituido, sulfinilo sustituido, sulfonilo sustituido, sulfinilamino sustituido, sulfonilamino sustituido, oxisulfinilamino sustituido, o, oxisulfonilamino sustituido; o una sal, éster, solvato, hidrato o prodroga farmacéuticamente aceptable del mismo.
ARP090102498A 2008-07-03 2009-07-03 Nucleosidos y nucleotidos biciclicos como agentes terapeuticos AR072688A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7797208P 2008-07-03 2008-07-03

Publications (1)

Publication Number Publication Date
AR072688A1 true AR072688A1 (es) 2010-09-15

Family

ID=41466563

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102498A AR072688A1 (es) 2008-07-03 2009-07-03 Nucleosidos y nucleotidos biciclicos como agentes terapeuticos

Country Status (6)

Country Link
US (3) US8119607B2 (es)
EP (1) EP2313102A2 (es)
AR (1) AR072688A1 (es)
TW (1) TW201008571A (es)
UY (1) UY31958A (es)
WO (1) WO2010002877A2 (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
NZ599402A (en) * 2009-09-21 2014-02-28 Gilead Sciences Inc 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011123493A1 (en) 2010-03-31 2011-10-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
BR112013001267A2 (pt) 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
CR20170278A (es) 2010-07-22 2017-09-29 Gilead Sciences Inc Métodos y compuestos para tratar infecciones virales por paramyxoviridae
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
KR101879887B1 (ko) * 2010-09-20 2018-07-18 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
WO2012087833A1 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
GB201114391D0 (en) * 2011-08-19 2011-10-05 Univ Warwick Method
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
EP3351552B1 (en) 2012-03-13 2021-05-19 Gilead Sciences, Inc. 2'-substituted carba-nucleoside analogs for antiviral treatment
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014059902A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
WO2014059901A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EP3251674A3 (en) * 2012-11-16 2018-02-21 BioCryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
US9732111B2 (en) 2012-11-19 2017-08-15 Merck Sharp & Dohme Corp. 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3421482A1 (en) 2012-12-21 2019-01-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2014204831A1 (en) 2013-06-18 2014-12-24 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
WO2016023522A2 (en) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
UA124966C2 (uk) 2015-03-06 2021-12-22 Атеа Фармасеутікалс, Інк. <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ
WO2016160646A1 (en) 2015-04-02 2016-10-06 Merck Sharp & Dohme Corp. Process for making phosphoramidate protected nucleoside compounds
SG10202001878WA (en) * 2015-09-16 2020-04-29 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
CN108289931B (zh) 2015-09-23 2022-10-11 默沙东公司 4’-取代的核苷逆转录酶抑制剂及其制备
TWI740910B (zh) 2016-03-09 2021-10-01 美商艾洛斯生物製藥公司 非環抗病毒劑
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
TW201811339A (zh) * 2016-08-12 2018-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
KR20230151050A (ko) 2017-02-01 2023-10-31 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
KR102460968B1 (ko) 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CR20200126A (es) * 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
CN113214262B (zh) * 2020-02-05 2023-07-07 华创合成制药股份有限公司 一种含有胍基的化合物及其制备方法和用途
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US20210292348A1 (en) 2020-02-18 2021-09-23 Gilead Sciences, Inc. Antiviral compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
KR20220164784A (ko) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
US20230241225A1 (en) 2020-06-15 2023-08-03 Metro International Biotech, Llc Anti-viral compounds and methods of use
WO2021257569A1 (en) * 2020-06-15 2021-12-23 Metro International Biotech, Llc Anti-viral compounds and methods of use
CR20220675A (es) 2020-06-24 2023-02-15 Gilead Sciences Inc Análogos de nucleósido de 1´- ciano y usos de los mismos
EP4200301A1 (en) 2020-08-24 2023-06-28 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
KR20230057411A (ko) 2020-08-27 2023-04-28 길리애드 사이언시즈, 인코포레이티드 바이러스 감염 치료를 위한 화합물 및 방법
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
WO2022098371A1 (en) * 2020-11-09 2022-05-12 Yan Matthew Prodrugs of 1'-substituted carba-nucleoside analogues for antiviral treatment
CN112592348B (zh) * 2020-12-21 2022-03-08 南京法恩化学有限公司 一种4-氨基吡咯并[2,1-f][1,2,4]三嗪的制备方法
WO2022221514A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR20240050362A (ko) 2021-08-20 2024-04-18 시오노기 앤드 컴파니, 리미티드 바이러스 증식 억제 작용을 갖는 뉴클레오사이드 유도체 및 그들의 프로드러그
WO2023102472A1 (en) * 2021-12-01 2023-06-08 The Scripps Research Institute Antiviral prodrugs and formulations thereof
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584369A (en) 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
US4854369A (en) * 1988-03-22 1989-08-08 Outboard Marine Corporation Apparatus for surrounding a foam pattern cluster with sand
US6174998B1 (en) * 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
ATE344271T1 (de) 1998-02-25 2006-11-15 Univ Emory 2'-fluoronukleoside
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
ES2319732T3 (es) 2000-04-13 2009-05-12 Pharmasset, Inc. Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
US6630476B2 (en) * 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
GB0019117D0 (en) * 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
WO2002057287A2 (en) * 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0113342D0 (en) 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 1
JP2005508633A (ja) * 2001-10-31 2005-04-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ３２６１６を用いる腫瘍形成障害および脈管形成障害の処置法および診断法
AU2002353165A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
EP1572705A2 (en) * 2002-01-17 2005-09-14 Ribapharm, Inc. Sugar modified nucleosides as viral replication inhibitors
CA2474563C (en) * 2002-02-13 2010-11-09 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
CA2477741A1 (en) * 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
CA2484921A1 (en) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
AU2003241621A1 (en) * 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
AU2003248907B2 (en) * 2002-07-11 2007-04-26 Merck & Co., Inc. Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds
US20060264389A1 (en) * 2002-07-16 2006-11-23 Balkrishen Bhat Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
TW200418498A (en) 2002-09-30 2004-10-01 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
EP1576138B1 (en) * 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
US20040259934A1 (en) * 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US20080275912A1 (en) * 2003-07-11 2008-11-06 Gareth Wyn Roberts Computer-Assisted Means for Providing Personalised Healthcare Products
CN1898240B (zh) * 2003-10-15 2011-08-03 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
BRPI0509576A (pt) * 2004-04-02 2007-05-29 Osi Pharm Inc composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1876894A1 (en) 2005-04-26 2008-01-16 The Board of Trustees of the University of Illinois Nucleoside compounds and methods of use thereof
CN101466710B (zh) 2005-12-02 2013-05-29 拜尔健康护理有限责任公司 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物
ES2545907T3 (es) 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
MX2009007333A (es) * 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
DK2155758T3 (da) * 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
TW200942243A (en) * 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents

Also Published As

Publication number Publication date
US20100035836A1 (en) 2010-02-11
US8501699B2 (en) 2013-08-06
WO2010002877A3 (en) 2010-11-04
US8415309B2 (en) 2013-04-09
EP2313102A2 (en) 2011-04-27
TW201008571A (en) 2010-03-01
US8119607B2 (en) 2012-02-21
US20130018013A1 (en) 2013-01-17
WO2010002877A2 (en) 2010-01-07
US20120122811A1 (en) 2012-05-17
UY31958A (es) 2010-01-29

Similar Documents

Publication Publication Date Title
AR072688A1 (es) Nucleosidos y nucleotidos biciclicos como agentes terapeuticos
AR050424A1 (es) Formulaciones antivirales de uso topico
JP2008505902A5 (es)
AR110010A2 (es) Composición farmacéutica formulada en una forma de dosis única de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
PE20091306A1 (es) Pirrolopirimidinas y pirrolopiridinas
MA35024B1 (fr) Dérivés de pyrrolo-[2,3-d]pyrimidine servant d&#39;inhibiteurs des kinases apparentés à la tropomyosine
JP2019501133A5 (es)
AR054559A1 (es) Derivados de purina como inhibidores del receptor a2a de adenosina
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
AR053232A1 (es) Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico.
AR035371A1 (es) Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
JP2017537949A5 (es)
MA38138A1 (fr) Dérivés inédits de quinolone
AR039648A1 (es) Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen
HN2010000653A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b
MEP36508A (en) Triazolopyrazine derivatives useful as anti-cancer agents
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
EA201171406A1 (ru) Спирооксетановые производные урацилсодержащих нуклеозидов
JP2015526472A5 (es)
ECSP099063A (es) Derivados de purina como agonistas de a2a
EA201170118A1 (ru) Циклопропильные ингибиторы полимеразы
CA2858789A1 (en) Treatment of inflammation
EA200970851A1 (ru) Еженедельное введение ингибиторов дипептидилпептидазы

Legal Events

Date Code Title Description
FA Abandonment or withdrawal